BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 25091619)

  • 21. Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review.
    Roque DM; Ratner ES; Silasi DA; Azodi M; Rutherford TJ; Schwartz PE; Nelson WK; Santin AD
    Gynecol Oncol; 2015 Jun; 137(3):392-400. PubMed ID: 25792179
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.
    McMeekin DS; Sill MW; Darcy KM; Stearns-Kurosawa DJ; Webster K; Waggoner S; Benbrook D
    Gynecol Oncol; 2007 Sep; 106(3):596-603. PubMed ID: 17597196
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes.
    Denduluri N; Low JA; Lee JJ; Berman AW; Walshe JM; Vatas U; Chow CK; Steinberg SM; Yang SX; Swain SM
    J Clin Oncol; 2007 Aug; 25(23):3421-7. PubMed ID: 17606971
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.
    Thomas E; Tabernero J; Fornier M; Conté P; Fumoleau P; Lluch A; Vahdat LT; Bunnell CA; Burris HA; Viens P; Baselga J; Rivera E; Guarneri V; Poulart V; Klimovsky J; Lebwohl D; Martin M
    J Clin Oncol; 2007 Aug; 25(23):3399-406. PubMed ID: 17606975
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mitoxantrone in the treatment of advanced uterine sarcoma. A phase II trial of the Gynecologic Oncology Group.
    Muss HB; Bundy BN; Adcock L; Beecham J
    Am J Clin Oncol; 1990 Feb; 13(1):32-4. PubMed ID: 2154921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer.
    Low JA; Wedam SB; Lee JJ; Berman AW; Brufsky A; Yang SX; Poruchynsky MS; Steinberg SM; Mannan N; Fojo T; Swain SM
    J Clin Oncol; 2005 Apr; 23(12):2726-34. PubMed ID: 15837987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trimetrexate in the treatment of recurrent or advanced leiomyosarcoma of the uterus: a phase II study of the Gynecologic Oncology Group.
    Smith HO; Blessing JA; Vaccarello L
    Gynecol Oncol; 2002 Jan; 84(1):140-4. PubMed ID: 11748990
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase II trial of ixabepilone in Asian patients with advanced gastric cancer previously treated with fluoropyrimidine-based chemotherapy.
    Kim YH; Muro K; Yasui H; Chen JS; Ryu MH; Park SH; Chu KM; Choo SP; Sanchez T; DelaCruz C; Mukhopadhyay P; Lainas I; Li CP
    Cancer Chemother Pharmacol; 2012 Oct; 70(4):583-90. PubMed ID: 22886073
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systematic chemotherapy for inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma: a systematic review.
    Gupta AA; Yao X; Verma S; Mackay H; Hopkins L;
    Clin Oncol (R Coll Radiol); 2013 Jun; 25(6):346-55. PubMed ID: 23295078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study.
    Whitehead RP; McCoy S; Rivkin SE; Gross HM; Conrad ME; Doolittle GC; Wolff RA; Goodwin JW; Dakhil SR; Abbruzzese JL
    Invest New Drugs; 2006 Nov; 24(6):515-20. PubMed ID: 16699973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase II clinical trial of ixabepilone (Ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma.
    Huang H; Menefee M; Edgerly M; Zhuang S; Kotz H; Poruchynsky M; Huff LM; Bates S; Fojo T
    Clin Cancer Res; 2010 Mar; 16(5):1634-41. PubMed ID: 20179242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II trial of paclitaxel in leiomyosarcoma of the uterus: a gynecologic oncology group study.
    Sutton G; Blessing JA; Ball H
    Gynecol Oncol; 1999 Sep; 74(3):346-9. PubMed ID: 10479491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
    Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors.
    Rivera E; Lee J; Davies A
    Oncologist; 2008 Dec; 13(12):1207-23. PubMed ID: 19088324
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II study of paclitaxel in combination with carboplatin for patients with recurrent or persistent uterine sarcoma.
    Yoo HJ; Lim MC; Lim S; Park JY; Kang S; Park SY; Seo SS
    Arch Gynecol Obstet; 2012 Dec; 286(6):1529-35. PubMed ID: 22825691
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Phase II Multi-Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma.
    Burotto M; Edgerly M; Velarde M; Balasubramaniam S; Drabkin H; Gormaz JG; O'Sullivan C; Madan R; Fojo T
    Oncologist; 2017 Aug; 22(8):888-e84. PubMed ID: 28679644
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical experience with epothilones in patients with breast cancer.
    Buzdar AU
    Clin Breast Cancer; 2008 Mar; 8 Suppl 2():S71-8. PubMed ID: 18637402
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas.
    Peereboom DM; Supko JG; Carson KA; Batchelor T; Phuphanich S; Lesser G; Mikkelsen T; Fisher J; Desideri S; He X; Grossman SA;
    J Neurooncol; 2010 Nov; 100(2):261-8. PubMed ID: 20449631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II trial of etoposide in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
    Thigpen T; Blessing JA; Yordan E; Valea F; Vaccarello L
    Gynecol Oncol; 1996 Oct; 63(1):120-2. PubMed ID: 8898180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ixabepilone plus capecitabine for breast cancer patients with an early metastatic relapse after adjuvant chemotherapy: two clinical trials.
    Fornier M
    Clin Breast Cancer; 2010 Oct; 10(5):352-8. PubMed ID: 20920979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.